Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Stem Cell (CSC) Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PROM1/CD133 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PROM1 Extracellular Domain (EC1 & EC2) Recombinant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View PROM1 Products |
| Gene Delivery | PROM1 Lentivirus Premade Particles Full-length ORF for stable cell line construction (Flow Cytometry & Cell-based assays). |
View PROM1 Products |
| Benchmark Ab | Anti-PROM1 Recombinant Antibody (Clone AC133 sequence) Recombinant positive control for epitope-specific binding. |
View PROM1 Products |
| Validator | PROM1 siRNA Set For knockdown verification in functional assays. |
View PROM1 Products |
| Related Target A | PROM2 Homolog of PROM1. Essential for off-target selectivity and counter-screening panels. |
View PROM2 Products |
| Related Target B | CD44 Co-expressed cancer stem cell marker. Synergistic target for bispecific and combination therapies. |
View CD44 Products |
| Related Target C | EpCAM Epithelial cell adhesion molecule. Target for bispecific platforms (e.g., EpCAM x CD133) in solid tumors. |
View EpCAM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Epitope Binding (e.g., AC133) | HEK293 mammalian expression host ensures native post-translational modifications and proper folding. |
| Multi-pass Membrane Protein Conformation | Lentiviral transduction vectors for robust surface expression of full-length PROM1 in target cell lines. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (AC133 biosimilar) included for functional validation. |
| False Positives / Off-Target Binding | Validated siRNA sets for specificity checks, alongside recombinant PROM2 homolog panels. |
Live PROM1/CD133 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PROM1/CD133 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting cancer stem cell (CSC) niches to overcome chemoresistance and tumor recurrence.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Ambrx (Johnson & Johnson), Heidelberg Pharma | Glioblastoma, Colorectal Cancer, Ovarian Cancer | Internalization Assay (Requires high-purity, natively glycosylated ECD-Fc proteins) |
| CAR-T / Cell Therapies | Sorrento Therapeutics, Academic Institutions | Hepatocellular Carcinoma, Brain Tumors | In vitro killing assays (Requires Lentivirus-transduced stable cell lines expressing full-length PROM1) |
| Bispecific Antibodies | Various Biotechs | Solid Tumors, Gastrointestinal Cancer | Selectivity Screening (Requires PROM1 vs. PROM2 homolog panels to prevent off-target toxicity) |